Intro paragraph
Narayana Health reported strong top-line growth in Q3 FY26 driven by India, Cayman and recent UK consolidation. Revenue rose to ₹21,512 Mn, while adjusted EBITDA improved, but PAT was affected by one-time acquisition costs and exceptional items. Operational wins in cardiac care and a growing international footprint underpinned the quarter.
Key Highlights
- Consolidated operating revenue at ₹21,512 Mn in Q3 FY26, up 61.2% YoY and 30.9% QoQ.
- Consolidated adjusted EBITDA (with UK) ₹4,662 Mn, a 43.1% increase YoY; adjusted EBITDA margin at 21.7%.
- Reported consolidated EBITDA ₹3,904 Mn at 18.2% margin; reported PAT ₹1,281 Mn (6.0% margin), down from prior year due to one‑time costs.
- Consolidated total borrowings less cash & bank balance and investments (net debt) ₹22,321 Mn as of 31 Dec 2025; net debt-to-equity ratio 0.53.
- Operational milestones: 244 robotic cardiac surgeries (+35% QoQ), 48 TAVIs (+50% YoY), first heart transplant at Ahmedabad completed in Dec‑25.
- UK operations consolidated from 6 Nov 2025; acquisition-related one-time costs highlighted in results.
Financial Summary
Use styled table
| Metric | Current | Previous | Change | Trend |
|---|---|---|---|---|
| Total Operating Revenue (Consolidated) | ₹21,512 Mn (Q3 FY26) | ₹13,346 Mn (Q3 FY25) | +61.2% YoY | Up |
| Adj. EBITDA (With UK) | ₹4,662 Mn | ₹3,257 Mn | +43.1% YoY | Up |
| Consolidated EBITDA (Reported) | ₹3,904 Mn | ₹3,257 Mn | +19.9% YoY | Up |
| Reported PAT | ₹1,281 Mn | ₹1,936 Mn | -33.9% YoY | Down |
| Adjusted PAT | ₹2,548 Mn | ₹1,936 Mn | +31.6% YoY | Up |
| Net Debt (Total borrowings less cash & investments) | ₹22,321 Mn (31 Dec 2025) | Not disclosed | Not disclosed | Monitor |
Business Performance
Narayana’s core India hospital network continued to drive volumes and revenue growth. The group cites about 6,245 total capacity beds across its footprint and roughly 55 facilities, supported by ~20,500 staff. India hospital revenues increased and ARPOB improved versus prior year. Integrated care and insurance businesses showed revenue traction, while Cayman operations delivered significant revenue growth in US dollars but reported a small negative EBITDA for Q3 (CIHL EBITDA US$ -1.5 Mn). The UK portfolio was consolidated from the acquisition effective 6 Nov 2025 and contributed materially to revenue and balance sheet size in the quarter.
Operational highlights included a strong uptick in complex cardiac procedures: 244 robotic cardiac surgeries (up 35% QoQ), 48 TAVIs (up 50% YoY), and completion of the first heart transplant at the Ahmedabad multispecialty hospital. Cluster-level data shows varied growth across regions with Southern cluster contributing a major share of hospital revenues.
Management Commentary
Management presented the quarter as a step-change driven by organic recovery and strategic acquisitions. They emphasized integration of the UK business, continued expansion of specialty services, and digital transformation initiatives. The company acknowledged one-time acquisition costs and exceptional items (e.g., new labor code impact) that weighed on reported PAT, while adjusted metrics show improved underlying profitability. Management also flagged the group’s foreign currency borrowings and said they are focused on cash conversion and cost discipline going forward.
Positives
- Strong consolidated revenue growth (61.2% YoY) from India, Cayman and UK contributions.
- Adjusted EBITDA increased notably, reflecting operating leverage as volumes recovered.
- Clinical milestones and higher-complexity procedures support higher-value care mix.
- Scale-up of integrated care and insurance lines showing sequential improvement.
Risks
- One-time acquisition and integration costs reduced reported PAT this quarter; further integration expenses could persist.
- Foreign currency exposure: material debt denominated in USD (US$119 Mn) and GBP (GBP £150 Mn).
- Cayman and some UK sites are early in the integration phase and reported losses or low EBITDA in Q3.
- Net debt remains elevated (₹22,321 Mn); balance sheet metrics will need monitoring as acquisitions are absorbed.
Conclusion
This quarter shows Narayana Health moving into a larger phase, with meaningful revenue gains and improved adjusted profitability as new geographies and businesses come on board. Operational strengths in cardiac and specialty care are driving higher-value procedures, while integrated care is scaling up. Investors should weigh the positive top-line momentum and clinical achievements against integration risks, one-time costs and elevated leverage. Execution on UK integration, currency management and cash conversion will shape the near-term outlook.
Disclaimer
This post is for educational purposes only and is not investment advice.
Indian Stock Results 